SCHEMBL570839

SCHEMBL570839

COC(=O)CNS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
HPGD P15428 2/20 0.73
KDM4E B2RXH2 1/20 0.73
NPC1 O15118 1/20 0.73
GAA P10253 1/20 0.73
RAB9A P51151 1/20 0.73
L3MBTL1 Q9Y468 1/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
LMNA P02545 1/20 0.54
HTT P42858 1/20 0.54
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MMP1 P03956 1/20 0.52
MMP2 P08253 1/20 0.52
MMP9 P14780 1/20 0.52
MMP8 P22894 1/20 0.52
MMP13 P45452 1/20 0.52
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257480 0.87 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL7383813 0.85 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL24762008 0.85 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL24762895 0.85 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL28677877 0.85 KDM4E (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL24762900 0.85 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL3239227 0.84 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL10767031 0.84 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HPGDKDM4ENPC1
SCHEMBL2627764 0.83 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2GAAL3MBTL1MEN1
SCHEMBL8575945 0.83 MAPT (0.63) ALDH1A1HPGDKDM4EGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119039221-A Synthesis method of roflumilast 沈阳药科大学 2024-11-29 CN claimed
CN-113717102-B New preparation method of isoquinoline compound 南通常佑药业科技有限公司 2024-07-26 CN claimed
CN-117825530-A Method for detecting methyl tosylglycine 中山奕安泰医药科技有限公司 2024-04-05 CN claimed
CN-108884047-B Intermediates for the synthesis of aryl or heteroaryl substituted 5-hydroxy-1, 7-naphthyridine compounds and methods for their preparation 沈阳三生制药有限责任公司 2022-03-08 CN claimed
CN-113717102-A Novel preparation method of isoquinoline compound 南通常佑药业科技有限公司 2021-11-30 CN claimed
EP-3275881-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2021-08-04 EP claimed
EP-3287456-B1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) 2020-08-26 EP claimed
CN-111499514-A Preparation method of intermediate of roxasistat 连云港润众制药有限公司 2020-08-07 CN claimed
CN-106146490-B 5- hydroxyl -1,7- naphthyridine compounds, preparation method and its pharmaceutical applications replaced by aryloxy group or heteroaryloxy 沈阳三生制药有限责任公司 2018-10-23 CN claimed
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-10-16 US claimed
CN-108341777-A Compound of isobioquin group and its application 四川科伦博泰生物医药股份有限公司 2018-07-31 CN claimed
US-9994566-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) 2018-06-12 US claimed
US-20180118738-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 US claimed
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) 2018-05-03 US claimed
EP-3287456-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) 2018-02-28 EP claimed
EP-3275881-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) 2018-01-31 EP claimed
CN-106146490-A 5-hydroxyl-1,7-naphthyridine compounds, its preparation method and the pharmaceutical applications thereof replaced by aryloxy group or heteroaryloxy 沈阳三生制药有限责任公司 2016-11-23 CN claimed
EP-4739688-A2 TRIAZOLO WRN INHIBITORS Nimbus Wadjet, Inc. (US) 2026-05-13 EP disclosed
US-4543422-A ESTER INTERCHANGE OF A VINYL ESTER AND ALCOHOLATE OR PHENOLATE OF ALUMINUM, ZIRCONIUM, ALLIED COLLOIDS LIMITED (GB) 1985-09-24 US disclosed
EP-0118639-A1 Synthesis of acrylic or methacrylic acid esters Ciba Specialty Chemicals Water Treatments Limited (GB) 1984-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118739-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 ALDH1A1 204/4885SMN1; SMN2 4001/4885HPGD 50/4885
US-10100051-B2 Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof HIF1AN, EGLN3, EGLN2 ALDH1A1 204/4885SMN1; SMN2 4001/4885HPGD 50/4885
US-20180118738-A1 COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF HIF1AN, EGLN3, EGLN2 ALDH1A1 119/4885SMN1; SMN2 3960/4885HPGD 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.